{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1182.106","meta":{"versionId":"5","lastUpdated":"2018-10-26T01:14:09.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"Change Healthcare Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2018-10-26"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1182.106","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1182.106"}],"version":"20181026","name":"AndrogenDeprivationTherapy","title":"Androgen Deprivation Therapy","status":"active","experimental":false,"date":"2018-10-26T01:00:04-04:00","publisher":"Change Healthcare Steward","description":"Value set developed to support MIPS Q104 measure.","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Androgen Deprivation Therapy),(Data Element Scope: Medications),(Inclusion Criteria: Androgen Deprivation Therapy),(Exclusion Criteria: n/a)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","concept":[{"code":"J9217","display":"Leuprolide acetate (for depot suspension), 7.5 mg"},{"code":"J9218","display":"Leuprolide acetate, per 1 mg"}]}]},"expansion":{"identifier":"urn:uuid:de2cb4db-1562-47f5-b4b5-2cba6a83e657","timestamp":"2023-12-10T22:39:00-05:00","total":2,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"J9217","display":"Leuprolide acetate (for depot suspension), 7.5 mg"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"J9218","display":"Leuprolide acetate, per 1 mg"}]}}